187 related articles for article (PubMed ID: 34746153)
1.
Xie X; Tang Y; Sheng J; Shu P; Zhu X; Cai X; Zhao C; Wang L; Huang X
Front Cell Dev Biol; 2021; 9():761758. PubMed ID: 34746153
[TBL] [Abstract][Full Text] [Related]
2. Co-mutation of TP53 and TTN is Correlated with the Efficacy of Immunotherapy in Lung Squamous Cell Carcinoma.
Ying K; Zou L; Wang D; Wang R; Qian J
Comb Chem High Throughput Screen; 2023 Oct; ():. PubMed ID: 37904553
[TBL] [Abstract][Full Text] [Related]
3. Bioinformatic Analysis of Immune Significance of RYR2 Mutation in Breast Cancer.
Xu Z; Xiang L; Wang R; Xiong Y; Zhou H; Gu H; Wang J; Peng L
Biomed Res Int; 2021; 2021():8072796. PubMed ID: 34888385
[TBL] [Abstract][Full Text] [Related]
4. Mutations in the
Zou S; Ye J; Hu S; Wei Y; Xu J
Int J Gen Med; 2022; 15():19-31. PubMed ID: 35018111
[TBL] [Abstract][Full Text] [Related]
5. Mucin 4 mutation is associated with tumor mutation burden and promotes antitumor immunity in colon cancer patients.
Peng L; Li Y; Gu H; Xiang L; Xiong Y; Wang R; Zhou H; Wang J
Aging (Albany NY); 2021 Mar; 13(6):9043-9055. PubMed ID: 33714943
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Value of MUC16 Mutation and Its Correlation with Immunity in Hepatocellular Carcinoma Patients.
Liu B; Dong Z; Lu Y; Ma J; Ma Z; Wang H
Evid Based Complement Alternat Med; 2022; 2022():3478861. PubMed ID: 36034941
[TBL] [Abstract][Full Text] [Related]
7. CSMD3 is Associated with Tumor Mutation Burden and Immune Infiltration in Ovarian Cancer Patients.
Lu N; Liu J; Xu M; Liang J; Wang Y; Wu Z; Xing Y; Diao F
Int J Gen Med; 2021; 14():7647-7657. PubMed ID: 34764678
[TBL] [Abstract][Full Text] [Related]
8. FLG Gene Mutation Up-regulates the Abnormal Tumor Immune Response and Promotes the Progression of Prostate Cancer.
Zhang P; An Z; Sun C; Xu Y; Zhang Z
Curr Pharm Biotechnol; 2022; 23(14):1658-1670. PubMed ID: 35422210
[TBL] [Abstract][Full Text] [Related]
9. EP300 mutation is associated with tumor mutation burden and promotes antitumor immunity in bladder cancer patients.
Zhu G; Pei L; Li Y; Gou X
Aging (Albany NY); 2020 Feb; 12(3):2132-2141. PubMed ID: 32012118
[TBL] [Abstract][Full Text] [Related]
10.
Sun Y; Li L; Yao W; Liu X; Yang Y; Ma B; Xue D
Front Genet; 2021; 12():762160. PubMed ID: 34795697
[TBL] [Abstract][Full Text] [Related]
11. Genomic landscape and prognosis of patients with
Fan Z; Zhang Q; Feng L; Wang L; Zhou X; Han J; Li D; Liu J; Zhang X; Zuo J; Zou X; Cai Y; Sun Y; Wang Y
Ann Transl Med; 2022 Feb; 10(4):188. PubMed ID: 35280362
[TBL] [Abstract][Full Text] [Related]
12.
Xue D; Lin H; Lin L; Wei Q; Yang S; Chen X
Transl Cancer Res; 2021 Mar; 10(3):1284-1294. PubMed ID: 35116455
[TBL] [Abstract][Full Text] [Related]
13. Cancer type-dependent correlations between TP53 mutations and antitumor immunity.
Li L; Li M; Wang X
DNA Repair (Amst); 2020 Apr; 88():102785. PubMed ID: 32007736
[TBL] [Abstract][Full Text] [Related]
14. Tumor Mutation Burden, Immune Cell Infiltration, and Construction of Immune-Related Genes Prognostic Model in Head and Neck Cancer.
Jiang AM; Ren MD; Liu N; Gao H; Wang JJ; Zheng XQ; Fu X; Liang X; Ruan ZP; Tian T; Yao Y
Int J Med Sci; 2021; 18(1):226-238. PubMed ID: 33390791
[No Abstract] [Full Text] [Related]
15. Aggregate analysis based on TCGA: TTN missense mutation correlates with favorable prognosis in lung squamous cell carcinoma.
Cheng X; Yin H; Fu J; Chen C; An J; Guan J; Duan R; Li H; Shen H
J Cancer Res Clin Oncol; 2019 Apr; 145(4):1027-1035. PubMed ID: 30810839
[TBL] [Abstract][Full Text] [Related]
16. Integrative Genomic and Transcriptomic Analyses of Tumor Suppressor Genes and Their Role on Tumor Microenvironment and Immunity in Lung Squamous Cell Carcinoma.
Kim A; Lim SM; Kim JH; Seo JS
Front Immunol; 2021; 12():598671. PubMed ID: 33717076
[TBL] [Abstract][Full Text] [Related]
17. Titin mutation in circulatory tumor DNA is associated with efficacy to immune checkpoint blockade in advanced non-small cell lung cancer.
Su C; Wang X; Zhou J; Zhao J; Zhou F; Zhao G; Xu X; Zou X; Zhu B; Jia Q
Transl Lung Cancer Res; 2021 Mar; 10(3):1256-1265. PubMed ID: 33889507
[TBL] [Abstract][Full Text] [Related]
18. LRP1B is a Potential Biomarker for Tumor Immunogenicity and Prognosis of HCC Patients Receiving ICI Treatment.
Cheng Y; Tang R; Li X; Wang B; Cheng Y; Xiao S; Sun P; Yu W; Li C; Lin X; Zhu Y
J Hepatocell Carcinoma; 2022; 9():203-220. PubMed ID: 35345553
[TBL] [Abstract][Full Text] [Related]
19. SYNE1 mutation may enhance the response to immune checkpoint blockade therapy in clear cell renal cell carcinoma patients.
Li P; Xiao J; Zhou B; Wei J; Luo J; Chen W
Aging (Albany NY); 2020 Oct; 12(19):19316-19324. PubMed ID: 33031058
[TBL] [Abstract][Full Text] [Related]
20. Tumor mutation burden (TMB)-associated signature constructed to predict survival of lung squamous cell carcinoma patients.
Yan D; Chen Y
Sci Rep; 2021 Apr; 11(1):9020. PubMed ID: 33907270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
